Table 1.
Univariable analysis on APPLE data at baseline to 3 years
| Variable | No AVN | AVN | P-value |
|---|---|---|---|
| No (%) Median (25th, 75th) | No (%) Median (25th, 75th) | ||
| Baseline 25(OH)D (ng/mL) | 25.9 (18.9, 31.6) | 18.7 (15.1, 32.2) | 0.266 |
| 25(OH)D < 20 ng/mL | 52/184 (28.3%) | 9/17 (52.9%) | 0.034 |
| Minority status: non-Caucasian | 113/184 (61.4%) | 15/17 (88.2%) | 0.028 |
| Age (years) | 15.5 (13.7, 17.6) | 16.5 (14.5, 18.0) | 0.207 |
| Female | 153/184 (83.2%) | 14/17 (82.4%) | >0.999 |
| SLE duration (months) | 23.5 (8.0, 44.5) | 25.0 (7.0, 45.0) | 0.787 |
| SLEDAI | 4.0 (2.0, 6.0) | 4.0 (0.0, 8.0) | 0.779 |
| History of hypertension | 55/178 (30.9%) | 10/17 (58.8%) | 0.020 |
| History of glomerulonephritis | 58/183 (31.7%) | 12/17 (70.6%) | 0.001 |
| History of nephritis/nephrosis | 67/183 (36.6%) | 14/17 (82.4%) | <0.001 |
| Corticosteroid use | 148/183 (80.9%) | 15/17 (88.2%) | 0.744 |
| Triglycerides (mg/dL) | 99.5 (74, 130.0) | 145.5 (88.5, 161.0) | 0.050 |
| Total cholesterol (mg/dL) | 146.0 (124.0, 173.0) | 160.5 (145.5, 183.0)f | 0.101 |
| C3 (mg/dL) | 99.0 (85.0, 122.0) | 108.5 (99.5, 115.0) | 0.175 |
| C4 (mg/dL) | 13.7 (9.0, 19.) | 19.3 (15.1, 22.9) | 0.017 |
| Baseline Homocysteine (mcmol/L) | 6.7 (5.6, 8.7) | 6.8 (5.4, 10.0) | 0.538 |
| Latitude (°N) | 40.7 (37.4, 40.9) | 37.4 (36.0, 40.0) | 0.004 |